Professional
Added to YB: 2026-07-07
Pitch date: 2026-03-31
MRK [bullish]
Merck & Co., Inc.
+5.62%
current return
Author Info
No bio for this author
Company Info
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands.
Market Cap
$320.0B
Pitch Price
$120.03
Price Target
N/A
Dividend
2.62%
EV/EBITDA
12.14
P/E
36.23
EV/Sales
5.53
Sector
Pharmaceuticals
Category
growth
Baron Health Care Fund New Position: Merck & Co., Inc.
MRK (new position): Large-cap pharma; Keytruda ~50% of rev ($31B in 2025) faces 2028 patent cliff. Mgmt managing via M&A (5 acquisitions incl Verona, Terns) & pipeline—20+ new drivers w/ $70B+ potential by mid-2030s. 12-18mo data readouts add visibility. Trades 12x trough 2029 EPS; multiple expansion expected.
Read full article (1 min)